Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 6/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.47 |
| ▸ | CACNA1A | O00555 | 3/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779314 | 0.90 | CACNA2D1 (0.46) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL4793339 | 0.83 | EPHX2 (0.45) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL4901052 | 0.83 | DPP8 (0.46) | CACNA2D1CACNB1CACNA1BCACNA1CDPP8 | |
| SCHEMBL4795558 | 0.81 | DPP8 (0.45) | CACNA2D1CACNB1CACNA1BCACNA1CDPP8 | |
| SCHEMBL4772655 | 0.81 | DPP8 (0.48) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL4772281 | 0.81 | KMT2A (0.47) | CACNA2D1CACNB1CACNA1BCACNA1CDPP8 | |
| SCHEMBL4779208 | 0.81 | DPP8 (0.47) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL4911475 | 0.80 | DPP8 (0.44) | CACNA2D1CACNB1CACNA1BCACNA1CDPP8 | |
| SCHEMBL4773302 | 0.78 | CACNA2D1 (0.50) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL4775817 | 0.78 | CACNA2D1 (0.54) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | claimed |
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | CACNA2D1 4234/4885CACNB1 2893/4885CACNA1B 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.